Lichtenstein SJ - Search Results

1

Lichtenstein SJ, Warman R, Wagner RS. Lichtenstein SJ, et al. J Pediatr Ophthalmol Strabismus. 2022 May-Jun;59(3):142-144. doi: 10.3928/01913913-20220325-01. Epub 2022 May 1. J Pediatr Ophthalmol Strabismus. 2022. PMID: 35603945 No abstract available.

2

Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies.

Lichtenstein SJ, Wagner RS, Jamison T, Bell B, Stroman DW. Lichtenstein SJ, et al. Adv Ther. 2007 Sep-Oct;24(5):1098-111. doi: 10.1007/BF02877716. Adv Ther. 2007. PMID: 18029337

3

Controlling contagious bacterial conjunctivitis.

Lichtenstein SJ, Dorfman M, Kennedy R, Stroman D. Lichtenstein SJ, et al. J Pediatr Ophthalmol Strabismus. 2006 Jan-Feb;43(1):19-26. doi: 10.3928/01913913-20060101-02. J Pediatr Ophthalmol Strabismus. 2006. PMID: 16491721

4

Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin.

Wagner RS, Granet DB, Lichtenstein SJ, Jamison T, Dajcs JJ, Gross RD, Cockrum P. Wagner RS, et al. Among authors: lichtenstein sj. Clin Ophthalmol. 2010 Feb 2;4:41-5. doi: 10.2147/opth.s9244. Clin Ophthalmol. 2010. PMID: 20169048 Free PMC article.

5

Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.

Lichtenstein SJ, De Leon L, Heller W, Marshall B, Cupp G, Foster K, McLean C, Levy S, Stroman DW. Lichtenstein SJ, et al. J Pediatr Ophthalmol Strabismus. 2012 Mar-Apr;49(2):88-97. doi: 10.3928/01913913-20111101-02. Epub 2011 Nov 8. J Pediatr Ophthalmol Strabismus. 2012. PMID: 22074357

6

Acute conjunctivitis.

Lichtenstein SJ, Granet D, Gold R. Lichtenstein SJ, et al. J Pediatr Ophthalmol Strabismus. 2004 May-Jun;41(3):134-8. doi: 10.3928/0191-3913-20040501-03. J Pediatr Ophthalmol Strabismus. 2004. PMID: 15206597 No abstract available.

7

Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients.

Lichtenstein SJ, Rinehart M; Levofloxacin Bacterial Conjunctivitis Study Group. Lichtenstein SJ, et al. J AAPOS. 2003 Oct;7(5):317-24. doi: 10.1016/s1091-8531(03)00168-x. J AAPOS. 2003. PMID: 14566313 Clinical Trial.

8

A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.

Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT; Levofloxacin Bacterial Conjunctivitis Active Control Study Group. Schwab IR, et al. Among authors: lichtenstein sj. Ophthalmology. 2003 Mar;110(3):457-65. doi: 10.1016/S0161-6420(02)01894-8. Ophthalmology. 2003. PMID: 12623805 Clinical Trial.

9

Fluoroquinolones compared to 1% azithromycin in DuraSite for bacterial conjunctivitis.

Lichtenstein SJ, Granet DB. Lichtenstein SJ, et al. Clin Ophthalmol. 2008 Mar;2(1):241-2. doi: 10.2147/opth.s2819. Clin Ophthalmol. 2008. PMID: 19668414 Free PMC article. No abstract available.

10

Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab.

Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ. Ittiara S, et al. Among authors: lichtenstein sj. J AAPOS. 2013 Jun;17(3):323-5. doi: 10.1016/j.jaapos.2013.01.004. Epub 2013 Apr 19. J AAPOS. 2013. PMID: 23607977

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters